Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cytokinetics (CYTK) EBIT: 2009-2024

Historic EBIT for Cytokinetics (CYTK) over the last 16 years, with Dec 2024 value amounting to -$536.2 million.

  • Cytokinetics' EBIT fell 18.43% to -$166.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$572.9 million, marking a year-over-year decrease of 9.21%. This contributed to the annual value of -$536.2 million for FY2024, which is 8.07% down from last year.
  • Cytokinetics' EBIT amounted to -$536.2 million in FY2024, which was down 8.07% from -$496.2 million recorded in FY2023.
  • Cytokinetics' 5-year EBIT high stood at -$93.9 million for FY2020, and its period low was -$536.2 million during FY2024.
  • Over the past 3 years, Cytokinetics' median EBIT value was -$496.2 million (recorded in 2023), while the average stood at -$452.2 million.
  • Its EBIT has fluctuated over the past 5 years, first climbed by 4.98% in 2020, then plummeted by 98.33% in 2021.
  • Yearly analysis of 5 years shows Cytokinetics' EBIT stood at -$93.9 million in 2020, then crashed by 98.33% to -$186.3 million in 2021, then plummeted by 74.01% to -$324.2 million in 2022, then plummeted by 53.05% to -$496.2 million in 2023, then declined by 8.07% to -$536.2 million in 2024.